Search Results - "Bies, Robert R"

Simulating realistic patient profiles from pharmacokinetic models by a machine learning postprocessing correction of residual variability by Kaikousidis, Christos, Bies, Robert R., Dokoumetzidis, Aristides

“…We address the problem of model misspecification in population pharmacokinetics (PopPK), by modeling residual unexplained variability (RUV) by machine learning…”
Get full text

Deep Learning Methods Applied to Drug Concentration Prediction of Olanzapine by Khusial, Richard, Bies, Robert R, Akil, Ayman

“…Pharmacometrics and the utilization of population pharmacokinetics play an integral role in model-informed drug discovery and development (MIDD). Recently,…”
Get full text

Anticholinergic Activity of 107 Medications Commonly Used by Older Adults by Chew, Marci L., Mulsant, Benoit H., Pollock, Bruce G., Lehman, Mark E., Greenspan, Andrew, Mahmoud, Ramy A., Kirshner, Margaret A., Sorisio, Denise A., Bies, Robert R., Gharabawi, Georges

“…The objective of this study was to measure the anticholinergic activity (AA) of medications commonly used by older adults. A radioreceptor assay was used to…”
Get full text

Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data by SAKURAI, Hitoshi, BIES, Robert R, UCHIDA, Hiroyuki, STROUP, Scott T, KEEFE, Richard S. E, RAJJI, Tarek K, SUZUKI, Takefumi, MAMO, David C, POLLOCK, Bruce G, WATANABE, Koichiro, MIMURA, Masaru

“…Antipsychotic drugs exert antipsychotic effects by blocking dopamine D2 receptors in the treatment of schizophrenia. However, effects of D2 receptor blockade…”
Get full text

Prediction of Nephropathy in Type 2 Diabetes: An Analysis of the ACCORD Trial Applying Machine Learning Techniques by Rodriguez‐Romero, Violeta, Bergstrom, Richard F., Decker, Brian S., Lahu, Gezim, Vakilynejad, Majid, Bies, Robert R.

“…Applying data mining and machine learning (ML) techniques to clinical data might identify predictive biomarkers for diabetic nephropathy (DN), a common…”
Get full text

exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity by Prado, Carla M. M, Lima, Isac S. F, Baracos, Vickie E, Bies, Robert R, McCargar, Linda J, Reiman, Tony, Mackey, John R, Kuzma, Michelle, Damaraju, Vijaya L, Sawyer, Michael B

“…Purpose Although body composition has emerged as an important predictor of drug efficacy and toxicity, explanations for this association are unclear. Our goal…”
Get full text

Application of machine learning to predict reduction in total PANSS score and enrich enrollment in schizophrenia clinical trials by Podichetty, Jagdeep T., Silvola, Rebecca M., Rodriguez‐Romero, Violeta, Bergstrom, Richard F., Vakilynejad, Majid, Bies, Robert R., Stratford, Robert E.

“…Clinical trial efficiency, defined as facilitating patient enrollment, and reducing the time to reach safety and efficacy decision points, is a critical…”
Get full text

Challenging the need for sustained blockade of dopamine D2 receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study by Tsuboi, Takashi, Suzuki, Takefumi, Bies, Robert R, Remington, Gary, Pollock, Bruce G, Mimura, Masaru, Uchida, Hiroyuki

“…Abstract Objective Blockade of dopamine D2 receptors with antipsychotics above 65% is associated with optimal chance of clinical response although recent data…”
Get full text

Sex, Race, and Smoking Impact Olanzapine Exposure by Bigos, Kristin L., Pollock, Bruce G., Coley, Kim C., Miller, Del D., Marder, Stephen R., Aravagiri, Manickam, Kirshner, Margaret A., Schneider, Lon S., Bies, Robert R.

“…Response to antipsychotics is highly variable, which may be due in part to differences in drug exposure. The goal of this study was to evaluate the magnitude…”
Get full text

Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients by Karas, Spinel, Etheridge, Amy S., Tsakalozou, Eleftheria, Ramírez, Jacqueline, Cecchin, Erika, van Schaik, Ron H.N., Toffoli, Giuseppe, Ratain, Mark J., Mathijssen, Ron H.J., Forrest, Alan, Bies, Robert R., Innocenti, Federico

“…Irinotecan (CPT-11) is an anticancer agent widely used in the treatment of a variety of adult solid tumors. The objective of this study was to develop an…”
Get full text

A model of anticholinergic activity of atypical antipsychotic medications by Chew, Marci L., Mulsant, Benoit H., Pollock, Bruce G., Lehman, Mark E., Greenspan, Andrew, Kirshner, Margaret A., Bies, Robert R., Kapur, Shitij, Gharabawi, Georges

“…Atypical antipsychotics clozapine, olanzapine, and quetiapine have significant affinity for the muscarinic receptors in vitro, while aripiprazole, risperidone,…”
Get full text

Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study by Feng, Yan, Pollock, Bruce G., Coley, Kim, Marder, Stephen, Miller, Del, Kirshner, Margaret, Aravagiri, Manickam, Schneider, Lon, Bies, Robert R.

“…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Risperidone metabolism is affected by blocking CYP2D6 and CYP3A4 (in CYP2D6 poor metabolizers) metabolizing enzymes…”
Get full text

Age and Sex Impact Clozapine Plasma Concentrations in Inpatients and Outpatients With Schizophrenia by Ismail, Zahinoor, B.M.Sc., M.D., F.R.C.P.C, Wessels, Alette M., Ph.D, Uchida, Hiroyuki, M.D., Ph.D, Ng, Wenzie, B.Sc., M.Pharm, Mamo, David C., M.D., M.Sc., F.R.C.P.C, Rajji, Tarek K., M.D., F.R.C.P.C, Pollock, Bruce G., M.D., Ph.D., F.R.C.P.C, Mulsant, Benoit H., M.D., M.S., F.R.C.P.C, Bies, Robert R., Pharm.D., Ph.D

“…Background Although clozapine is primarily used in a younger to mid-life population of patients with psychosis, there are limited data on the clinical…”
Get full text

Sex differences in the pharmacokinetics and pharmacodynamics of antidepressants: An updated review by Bigos, Kristin L., PhD, Pollock, Bruce G., MD, PhD, Stankevich, Beth A., BS, Bies, Robert R., PharmD, PhD

“…Abstract Background: An increasing number of studies have reported differences in the pharmacokinetics and/or pharmacodynamics of antidepressants between women…”
Get full text

Translocator Protein Blockade Reduces Prostate Tumor Growth by FAFALIOS, Arlee, AKHAVAN, Ardavan, PARWANI, Anil V, BIES, Robert R, MCHUGH, Kevin J, PFLUG, Beth R

“…Purpose: The transmembrane molecule, translocator protein (TSPO), has been implicated in the progression of epithelial tumors. TSPO gene expression is high in…”
Get full text

Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approach by Velez de Mendizabal, Nieves, Hutmacher, Matthew M, Troconiz, Iñaki F, Goñi, Joaquín, Villoslada, Pablo, Bagnato, Francesca, Bies, Robert R

“…Relapsing-remitting dynamics are a hallmark of autoimmune diseases such as Multiple Sclerosis (MS). A clinical relapse in MS reflects an acute focal…”
Get full text

Modelling the progression of illicit substance use patterns from real‐world evidence by Tummala, Hari Prabhath, Bies, Robert R., Ramanathan, Murali

“…Aims To investigate an innovative pharmacometrics approach that addresses the challenges of using real‐world evidence to model the progression of illicit…”
Get full text

Effect of Age, Weight, and CYP2C19 Genotype on Escitalopram Exposure by Jin, Yuyan, Pollock, Bruce G., Frank, Ellen, Cassano, Giovanni B., Rucci, Paola, Müller, Daniel J., Kennedy, James L., Forgione, Rocco Nicola, Kirshner, Margaret, Kepple, Gail, Fagiolini, Andrea, Kupfer, David J., Bies, Robert R.

“…The purpose of this study was to characterize escitalopram population pharmacokinetics (PK) in patients treated for major depression in a cross‐national,…”
Get full text

Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics by Li, Claire H, Stratford, Jr, Robert E, Velez de Mendizabal, Nieves, Cremers, Thomas I F H, Pollock, Bruce G, Mulsant, Benoit H, Remington, Gary, Bies, Robert R

“…Clozapine is highly effective in treatment-resistant schizophrenia, although, there remains significant variability in the response to this drug. To better…”
Get full text

Clozapine Exposure and the Impact of Smoking and Gender: A Population Pharmacokinetic Study by NG, Wenzie, UCHIDA, Hiroyuki, ISMAIL, Zahinoor, MAMO, David C, RAJJI, Tarek K, REMINGTON, Gary, SPROULE, Beth, POLLOCK, Bruce G, MULSANT, Benoit H, BIES, Robert R

“…The primary objective of this study was to evaluate the magnitude and variability of concentration exposure to clozapine and norclozapine in a real-world…”
Get full text